It is time to consider third-line options in antiretroviral-experienced paediatric patients?

Journal of the International AIDS Society

Volumn 14, Issue 1, 2011, Pages

  Van Zyl, Gert U ^a   Rabie, Helena ^b   Nuttall, James J ^c   Cotton, Mark F ^b,d  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d Children's Infectious Diseases Clinical Research Unit   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CD4 ANTIGEN; DARUNAVIR PLUS RITONAVIR; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RITONAVIR PLUS TIPRANAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CROSS-SECTIONAL STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; CASE CONTROL STUDY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; METHODOLOGY; MISSENSE MUTATION; PRESCHOOL CHILD; PREVALENCE; SOUTH AFRICA; TREATMENT FAILURE; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION, MISSENSE; PREVALENCE; RITONAVIR; SOUTH AFRICA; TREATMENT FAILURE; VIRAL LOAD;

EID: 81055149846     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-55     Document Type: Article

References (27)

1. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. Chadwick EG, Capparelli EV, Yogev R, Pinto JA, Robbins B, Rodman JH, Chen J, Palumbo P, Serchuck L, Smith E, Hughes M, P1030 team, AIDS 2008 22 2 249 255 10.1097/QAD.0b013e3282f2be1d 18097227
2. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. Ren Y, Nuttall JJ, Egbers C, Eley BS, Meyers TM, Smith PJ, Maartens G, McIlleron HM, J Acquir Immune Defic Syndr 2008 47 5 566 569 10.1097/QAI.0b013e3181642257 18197120 (Pubitemid 351442016)
3. Protease Inhibitor Resistance in South African Children With Virologic Failure. van Zyl GU, van der Merwe L, Claassen M, Cotton MF, Rabie H, Prozesky HW, Preiser W, Pediatr Infect Dis J 2009 28 12 1125 1127 10.1097/INF. 0b013e3181af829d 19779394
4. Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. van Zyl GU, Claassen M, Engelbrecht S, Laten JD, Cotton MF, Theron GB, Preiser W, J Med Virol 2008 80 6 942 946 10.1002/jmv.21157 18428139 (Pubitemid 351657002)
5. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program. Jaspan HB, Berrisford AE, Boulle AM, Pediatr Infect Dis J 2008 27 11 993 998 10.1097/INF.0b013e31817acf7b 18818556
6. Antiretroviral treatment for children with peripartum nevirapine exposure. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, Bwakura-Dangarembizi M, Chi BH, Musoke P, Kamthunzi P, Schimana W, Purdue L, Eshleman SH, Abrams EJ, Millar L, Petzold E, Mofenson LM, Jean-Philippe P, Violari A, N Engl J Med 2010 363 16 1510 1520 10.1056/NEJMoa1000931 20942667
7. Palumbo P, Violari A, Lindsey J, Hughes M, Jean-Philippe P, Mofenson L, Bwakura-Dangarembizi M, Kamthunzi P, Eshleman S, Purdue L, NVP-vs LPV/r-based ART among HIV+ Infants in Resource-limited Settings: The IMPAACT P1060 Trial 18th Conference on Retroviruses and Oppurtunistic Infections Boston, MA, USA 2011
8. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, Hunt G, Hu CC, Tsai WY, Morris L, Kuhn L, JAMA 304 10 1082 1090
9. Lopinavir/Ritonavir-based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-infected Naive Children: Rare Protease Inhibitor Resistance Mutations But High Lamivudine/Emtricitabine Resistance at the Time of Virologic Failure. Frange P, Briand N, Avettand-Fenoel V, Veber F, Moshous D, Mahlaoui N, Rouzioux C, Blanche S, Chaix ML, Pediatr Infect Dis J 2011 30 8 684 688 10.1097/INF.0b013e31821752d6 21427626
10. Mutation T74S in HIV-1 subtype B and C proteases resensitizes them to ritonavir and indinavir and confers fitness advantage. Soares EA, Santos AF, Gonzalez LM, Lalonde MS, Tebit DM, Tanuri A, Arts EJ, Soares MA, J Antimicrob Chemother 2009 64 5 938 944 10.1093/jac/dkp315 19710076
11. Anti-retroviral drug resistance-associated mutations among non-subtype B HIV-1-infected Kenyan children with treatment failure. Lwembe R, Ochieng W, Panikulam A, Mongoina CO, Palakudy T, Koizumi Y, Kageyama S, Yamamoto N, Shioda T, Musoke R, Owens M, Songok EM, Okoth FA, Ichimura H, J Med Virol 2007 79 7 865 872 10.1002/jmv.20912 17516531 (Pubitemid 46871541)
12. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy. Averbuch D, Schapiro JM, Lanier ER, Gradstein S, Gottesman G, Kedem E, Einhorn M, Grisaru-Soen G, Ofir M, Engelhard D, Grossman Z, Pediatr Infect Dis J 2006 25 11 1049 1056 10.1097/01.inf.0000243211.36690.d5 17072129 (Pubitemid 44657816)
13. Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa. Barth RE, Wensing AM, Tempelman HA, Moraba R, Schuurman R, Hoepelman AI, AIDS 2008 22 16 2210 2212 10.1097/QAD.0b013e328313bf87 18832885
14. High prevalence of antiretroviral drug resistance mutations in HIV-1 non-B subtype strains from African children receiving antiretroviral therapy regimen according to the 2006 revised WHO recommendations. Gody JC, Charpentier C, Mbitikon O, Si-Mohamed A, LeGoff J, Gresenguet G, Belec L, J Acquir Immune Defic Syndr 2008 49 5 566 569 10.1097/QAI.0b013e318183acae 19202461
15. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. Germanaud D, Derache A, Traore M, Madec Y, Toure S, Dicko F, Coulibaly H, Sylla M, Calvez V, Marcelin AG, J Antimicrob Chemother 2010 65 1 118 124 10.1093/jac/dkp412 19933171
16. In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine. Paredes R, Sagar M, Marconi VC, Hoh R, Martin JN, Parkin NT, Petropoulos CJ, Deeks SG, Kuritzkes DR, J Virol 2009 83 4 2038 2043 10.1128/JVI.02154-08 19019971
17. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA, New Microbiol 2004 27 2 Suppl 1 31 39 15646062 (Pubitemid 40090987)
18. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A, AIDS 2006 20 6 795 803 10.1097/01.aids. 0000218542.08845.b2 16549962 (Pubitemid 43731560)
19. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN, Antimicrob Agents Chemother 2009 53 6 2532 2538 10.1128/AAC.01374-08 19258274
20. Davies MA, Wood R, van Cutsem G, Giddy J, Eley B, Rabie H, Moultrie H, Technau K, Boulle A, Virologic failure and second-line antiretroviral therapy (ART) in children in South Africa: the international databases to evaluate AIDS (IeDEA) Southern Africa collaboration 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention Cape Town, South Africa 2009
21. Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G, J Acquir Immune Defic Syndr 2011 56 4 333 339 10.1097/QAI.0b013e31820dc0cc 21239995
22. Macrocytosis as an indicator of medication (zidovudine) adherence in patients with HIV infection. Romanelli F, Empey K, Pomeroy C, AIDS Patient Care STDS 2002 16 9 405 411 10.1089/108729102760330245 12396692
23. Macrocytosis in patients on stavudine. Eyer-Silva WA, Arabe J, Pinto JF, Morais-De-Sa CA, Scand J Infect Dis 2001 33 3 239 240 10.1080/00365540151061067 11303821 (Pubitemid 32258039)
24. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM, N Engl J Med 2001 344 7 472 480 10.1056/NEJM200102153440702 11172188 (Pubitemid 32164898)
25. Wiznia A, Samson P, Acosta E, Safety and efficacy of raltegravir inpediatric HIV infection: preliminary analysis from the international maternal pediatric adolescent AIDS clinical trial group 16th Conference on Retroviruses and Opportunistic Infections Montreal, Canada 2009
26. Improving treatment outcome for children with HIV. Calmy AL, Ford N, Lancet 2011 377 9777 1546 1548 10.1016/S0140-6736(11)60363-2 21511331
27. Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. Rodriguez CA, Koch S, Goodenow M, Sleasman JW, Immunol Res 2008 40 3 271 286 10.1007/s12026-007-0031-1 17952387 (Pubitemid 351903816)